In millions, except per share items | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K |
Revenues: |
Lorantis | | | | 51.6 | | | | |
Contract and license revenues | | | | | | 5.8 | 24.6 | 37.1 |
Contract and license revenues from Genmab | | | | | | 5.3 | | |
Other | | | | | | 0.0 | 14.9 | 5.2 |
Total revenues | 52.3 | 56.3 | 48.6 | 51.5 | 12.5 | 11.2 | 39.5 | 42.3 |
Revenue growth [+] | -7.0% | 15.6% | -5.5% | 312.5% | 11.6% | -71.7% | -6.7% | 88.4% |
Contract and license revenues | | | | | | -76.2% | -33.9% | 89.3% |
Cost of goods sold | 346.7 | 357.4 | 194.5 | 145.4 | 128.5 | 0.0 | 8.3 | 0.6 |
Gross profit | -294.4 | -301.1 | -145.9 | -93.9 | -116.0 | 11.2 | 31.2 | 41.7 |
Gross margin | -563.0% | -535.2% | -299.9% | -182.6% | -929.9% | 100.0% | 78.9% | 98.5% |
Selling, general and administrative [+] | 44.4 | 46.9 | 51.9 | 29.0 | 25.3 | 23.8 | 22.9 | 19.3 |
General and administrative | 44.4 | 46.9 | 51.9 | 29.0 | 25.3 | 23.8 | 22.9 | 19.3 |
Equity in earnings | -10.1 | | -1.0 | -6.3 | -19.8 | -15.0 | -50.6 | -7.3 |
Other operating expenses | | | | | | 104.3 | 110.2 | 38.6 |
EBITDA [+] | -330.0 | -330.5 | -179.5 | -110.9 | -142.2 | -115.7 | -141.6 | -19.0 |
EBITDA growth | -0.2% | 84.2% | 61.9% | -22.0% | 22.9% | -18.3% | 643.4% | -36.3% |
EBITDA margin | -631.0% | -587.5% | -368.9% | -215.5% | -1139.8% | -1035.4% | -358.7% | -45.0% |
Depreciation | 16.1 | 14.3 | 13.1 | 12.7 | 12.0 | 10.7 | 7.9 | 3.4 |
EBITA | -346.0 | -344.8 | -192.6 | -123.6 | -154.2 | -126.3 | -149.5 | -22.5 |
EBITA margin | -661.7% | -612.8% | -395.9% | -240.2% | -1236.1% | -1130.7% | -378.6% | -53.1% |
Amortization of intangibles | 2.9 | 3.3 | 6.3 | 5.6 | 6.8 | 5.6 | 3.1 | 1.2 |
EBIT [+] | -348.9 | -348.0 | -198.8 | -129.2 | -161.0 | -132.0 | -152.6 | -23.6 |
EBIT growth | 0.2% | 75.0% | 53.9% | -19.8% | 22.0% | -13.5% | 545.3% | -24.1% |
EBIT margin | -667.2% | -618.6% | -408.7% | -251.1% | -1291.0% | -1181.0% | -386.4% | -55.9% |
Non-recurring items | -151.8 | -152.1 | | | | | | |
Interest expense, net [+] | 6.2 | 6.2 | 4.7 | 4.2 | 12.8 | 11.8 | -9.4 | -20.1 |
Interest expense | 6.2 | 6.2 | 4.7 | 4.2 | 12.8 | 11.8 | 9.1 | 4.6 |
Interest income | | | | | | | 18.5 | 24.7 |
Other income (expense), net | 164.5 | 175.0 | 22.3 | -14.2 | -12.5 | 9.1 | -14.3 | 1.4 |
Pre-tax income | -38.7 | -27.1 | -181.3 | -147.7 | -186.4 | -134.7 | -157.4 | -2.1 |
Income taxes | -0.3 | 0.0 | 0.4 | 0.4 | 0.0 | 0.1 | 0.1 | 0.6 |
Tax rate | 0.7% | | | | | | | |
Net income | -38.5 | -27.1 | -181.7 | -148.0 | -186.4 | -134.7 | -157.5 | -2.7 |
Net margin | -73.6% | -48.1% | -373.5% | -287.7% | -1494.2% | -1205.9% | -399.1% | -6.4% |
|
Basic EPS [+] | ($0.30) | ($0.21) | ($1.50) | ($1.34) | ($2.29) | ($1.72) | ($2.09) | ($0.04) |
Growth | 40.5% | -85.8% | 11.8% | -41.3% | 32.9% | -17.8% | 5662.2% | -184.9% |
Diluted EPS [+] | ($0.30) | ($0.21) | ($1.50) | ($1.34) | ($2.29) | ($1.72) | ($2.09) | ($0.04) |
Growth | 40.5% | -85.8% | 11.8% | -41.3% | 32.9% | -17.8% | 5662.2% | -186.9% |
|
Shares outstanding (basic) [+] | 128.2 | 126.7 | 121.1 | 110.3 | 81.5 | 78.3 | 75.2 | 73.9 |
Growth | 1.2% | 4.6% | 9.8% | 35.4% | 4.1% | 4.1% | 1.8% | 3.4% |
Shares outstanding (diluted) [+] | 128.2 | 126.7 | 121.1 | 110.3 | 81.5 | 78.3 | 75.2 | 73.9 |
Growth | 1.2% | 4.6% | 9.8% | 35.4% | 4.1% | 4.1% | 1.8% | 1.0% |
|
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |